NEU 1.03% $19.30 neuren pharmaceuticals limited

Neuren Media and Analyst Coverage, page-1113

  1. 1,566 Posts.
    lightbulb Created with Sketch. 133
    It is always great to hear these firsthand stories. It seems that getting on Daybue earlier, and for longer leads to the most impact for patients. Many of the accounts communicate similar improvements when it comes to hand use, ability to walk and being able to communicate more often and with new words. It really shows that the underlying mechanism is working. The above poster sent a story about NTI's Rett Results which conveniently leave out these anchors in the CGI-I. The results with them included are less impressive.

    Their treatment is claiming to reduce neuroinflammation (which may do) but it is clear restore of function (such as hand use) only occurs if pathways in the brain are being slowly restored to a normalised state which makes the two compounds completely different. NTI are going for OD designation which I s
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.